As discussed below, discovery efforts for new inhibitors have typically been based on the structure of known protease substrates, presenting a substantial challenge for the development of ...

This programme is designed to advance next-generation vaccines, therapeutics, and other tools to combat Covid-19. The therapeutic, dubbed S-892216, leverages protease inhibitor technology to block the ...

Historically, most people started HIV treatment with two drugs from the NRTI class combined with either one NNRTI, one protease inhibitor or one integrase inhibitor – hence, ‘triple therapy’.

Shionogi & Co. Ltd. won a $375 million project agreement from the Rapid Response Partnership Vehicle to develop its 3CL protease inhibitor, S-892216, as a long-acting injectable for COVID-19 ...

Alpha1-proteinase inhibitor (human) 1000mg/vial; lyophilized pwd for IV infusion after reconstitution; preservative-free. Upper respiratory tract infection, UTI, nausea, pain, chills, cough ...

Shanghai Curegene Pharmaceutical Co. Ltd. has synthesized 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 ...

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Cocrystal Pharma (COCP – Research Report) today and set a price target of ...

After Discontinuation of Treatment with QRX003 Complete Reversal of Positive Clinical Improvements Across all Measured Endpoints Observed; Data Supports QRX003 Mechanis ...

Treatment-experienced (genotype 1): treat for 16 weeks if previously treated with an NS5A inhibitor (without prior NS3/4A protease inhibitor) or for 12 weeks if previously treated with an NS3/4A ...